Company Overview and News

 
ASX slides as banks, CSL weigh

2018-10-02 theage.com.au
The ASX dropped on Tuesday, with banks and CSL dragging the index back to a level last seen in mid September.
ASXFF MQBKY QABSD OISHY ILKAF MCQEF ILU OGFGY OISHF GXY GALXF ASXFY QABSY QUBSF QAN ARLUF ALL OGFGF ILKAY MQG ORG OSH

 
ASX slides as banks, CSL weigh

2018-10-02 watoday.com.au
The ASX dropped on Tuesday, with banks and CSL dragging the index back to a level last seen in mid September.
ASXFF MQBKY QABSD OISHY ILKAF MCQEF ILU OGFGY OISHF GXY GALXF ASXFY QABSY QUBSF QAN ARLUF ALL OGFGF ILKAY MQG ORG OSH

 
ASX slides as banks, CSL weigh

2018-10-02 smh.com.au
The ASX dropped on Tuesday, with banks and CSL dragging the index back to a level last seen in mid September.
ASXFF MQBKY QABSD OISHY ILKAF MCQEF ILU OGFGY OISHF GXY GALXF ASXFY QABSY QUBSF QAN ARLUF ALL OGFGF ILKAY MQG ORG OSH

 
Trade tariffs hit ASX as resource stocks fall

2018-09-18 theage.com.au
Australian shares closed the session lower on Tuesday as the announcement on further tariffs on China hit major materials and energy stocks.
WOPEF BLT SGQ OGFGY REG RSG BEPTF GALXF RMGGF WNARF WSA AOG BHPBF WTCHF WPL BCHEY WOPEY BPT GXY RMGGY BHP BBL BHP OGFGF BHPLF JRHHY EHE JHC ORG

 
Trade tariffs hit ASX as resource stocks fall

2018-09-18 smh.com.au
Australian shares closed the session lower on Tuesday as the announcement on further tariffs on China hit major materials and energy stocks.
WOPEF BLT SGQ OGFGY REG RSG BEPTF GALXF RMGGF WNARF WSA AOG BHPBF WTCHF WPL BCHEY WOPEY BPT GXY RMGGY BHP BBL BHP OGFGF BHPLF JRHHY EHE JHC ORG

2
Energy sector lifts ASX to higher week

2018-09-14 theage.com.au
Australian shares have rebounded from last week's $50 billion fall to close the week higher despite some of the major financial stocks weighing the index.
WOPEF RIO RIO SNMYF EVN IAG OGFGY RSG BEPTF RTPPF GALXF SUN RMGGF RTNTF CAHPF MS IAUGY WTCHF SNMCY WPL RGRNF BCHEY WOPEY BPT GXY IAUGF RMGGY RIO RRL OGFGF ORG

2
Energy sector lifts ASX to higher week

2018-09-14 smh.com.au
Australian shares have rebounded from last week's $50 billion fall to close the week higher despite some of the major financial stocks weighing the index.
WOPEF RIO RIO SNMYF EVN IAG OGFGY RSG BEPTF RTPPF GALXF SUN RMGGF RTNTF CAHPF MS IAUGY WTCHF SNMCY WPL RGRNF BCHEY WOPEY BPT GXY IAUGF RMGGY RIO RRL OGFGF ORG

 
Galaxy Resources Limited (GALXF) CEO Anthony Tse on Q2 2018 Results - Earnings Call Transcript

2018-08-30 seekingalpha
Ladies and gentlemen, thank you for standing by. Welcome to the Galaxy Resources Limited Half Year Results Conference Call. [Operator Instructions] I must advise you that this conference is being recorded today, Thursday, the 30th of August 2018.
GALXF GXY MS

 
Galan Lithium making its mark on 'one of the best places in Argentina's lithium triangle'

2018-08-28 proactiveinvestors.com.au
Galan Lithium Ltd (ASX:GLN) managing director JP Vargas speaks to Proactive Investors about the explorer’s potentially large scale Salar de Hombre Muerto Lithium Project in Argentina’s Catamarca Province, also known as the ‘lithium triangle.’
GLN GXY GALXF DMI

14
Deals of the day-Mergers and acquisitions

2018-08-27 reuters
Aug 27 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1030 GMT on Monday:
BGX GXY GALXF BGLF BX IOF MTTRY BGB

3
Galan Lithium reveals third director share increase this month

2018-08-21 proactiveinvestors.com.au
Galan Lithium Ltd (ASX:GLN) has revealed that managing director Juan Pablo Vargas de la Vega has increased his shareholding in the company through on-market purchases.
GLN RTPPF GXY GALXF RIO RIO RIO FMC RTNTF DMI

1
Galan Lithium to survey shallow brines at Argentine lithium project

2018-08-20 proactiveinvestors.com.au
Galan Lithium Ltd (ASX:GLN) has begun a new round of geophysical surveys aimed at extending brine units at its Salar de Hombre Muerto Lithium Project in Argentina’s Catamarca Province.
GLN GXY GALXF FMC DMI SQM

 
Wall Street’s Latest Short: Once-Hot Metal for Electric Cars - WSJ

2018-08-15 wsj
Investors have reaped gains this year from short bets on companies that produce lithium—a commodity used in the batteries that power electric vehicles and smartphones.
SFTBF GXY GALXF 9984 MS OROCF SFTBY

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...